article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

article thumbnail

Using DrugPatentWatch to Support Out-Licensing and Partnering Decisions

Drug Patent Watch

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How do patent thickets vary across different countries

Drug Patent Watch

” These dense webs of overlapping patent rights can significantly impact innovation, market entry, and competition across various industries and countries. Easier market entry: Less dense thickets may make it easier for new players to enter markets.

article thumbnail

TG shares tumble following licensing deal for MS drug

BioPharma Drive: Drug Pricing

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130
article thumbnail

LianBio to shut down, return cash to investors

BioPharma Drive: Drug Pricing

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing 182
article thumbnail

2025 Gynecology Licensing Trends Report: 150+ Deals by Company, Therapy & Tech

The Pharma Data

Comprehensive Report Reveals Key Trends in Gynecology Collaboration and Licensing Deals from 2016 to 2025 Gynecology Collaboration and Licensing Deals report offers a deep dive into the evolving landscape of partnerships in women’s health, providing unparalleled insights into over 150 strategic deals executed globally between 2016 and 2025.

article thumbnail

What you should know about the FDA’s Biological License Application Process

Reprocell

The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.